9B1A0E7C-F8DB-4FA0-9259-42A988D4E040
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 45.893561103810775
- age_years
- 50
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.429
- OXIDATIVE_PHOSPHORYLATION+0.424
- MYC_TARGETS_V1+0.405
- NOTCH_SIGNALING+0.404
- MYC_TARGETS_V2+0.373
- PROTEIN_SECRETION+0.327
- E2F_TARGETS+0.292
- UNFOLDED_PROTEIN_RESPONSE+0.286
- ADIPOGENESIS+0.284
- FATTY_ACID_METABOLISM+0.261
Top 10 suppressed
- KRAS_SIGNALING_DN-0.414
- MYOGENESIS-0.255
- ANGIOGENESIS-0.236
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.208
- SPERMATOGENESIS-0.197
- ALLOGRAFT_REJECTION-0.176
- INFLAMMATORY_RESPONSE-0.174
- COAGULATION-0.154
- ESTROGEN_RESPONSE_LATE-0.152
- APICAL_SURFACE-0.131
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A6FB1BEE-0D36-480C-8619-1FA82583FCD1 | — | — | 0.924 |
| 2 | 194676E1-632C-4B99-A9C8-80E36DD6C85E | — | — | 0.914 |
| 3 | 743F5644-F650-437A-B4AE-4972F88606D8 | — | — | 0.914 |
| 4 | 635170D3-D669-4165-B69C-9C9A246BFF11 | — | — | 0.902 |
| 5 | 72781523-C5BA-4B54-8410-E238B5F441B4 | — | — | 0.901 |
| 6 | 7AE107A7-8EA7-4920-A579-2337C007920D | — | — | 0.899 |
| 7 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.897 |
| 8 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.885 |
| 9 | SRR934941 | — | — | 0.883 |
| 10 | EA6A086B-F655-47E8-9E70-8A2D36FC2AE1 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.429 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.424 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.405 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.404 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.373 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.327 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.292 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.286 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.284 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.261 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.199 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.185 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.181 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.174 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.165 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.147 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.141 | Inavolisib | — uncovered |
| PEROXISOME | 0.118 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.116 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.115 | Idelalisib | — uncovered |